Cargando…

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis

The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auer, Michael, Hegen, Harald, Hotter, Anna, Löscher, Wolfgang, Berek, Klaus, Zinganell, Anne, Fava, Elena, Rhomberg, Paul, Deisenhammer, Florian, Di Pauli, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966083/ https://www.ncbi.nlm.nih.gov/pubmed/35370432 http://dx.doi.org/10.1177/11795735221084837

Ejemplares similares

SARS-CoV2 infection as a potential trigger for severe relapse in a patient with multiple sclerosis who stopped disease modifying treatment due to COVID-19 pandemic
por: Auer, Michael, et al.
Publicado: (2021)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
por: Auer, Michael, et al.
Publicado: (2021)

Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi
por: Berek, Klaus, et al.
Publicado: (2020)

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
por: Berek, Klaus, et al.
Publicado: (2021)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Serum hepcidin levels in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association
por: Di Pauli, Franziska, et al.
Publicado: (2021)

Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Cerebrospinal fluid protein in Guillain–Barré syndrome: Need for age‐dependent interpretation
por: Hegen, Harald, et al.
Publicado: (2020)

Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity
por: Berek, Klaus, et al.
Publicado: (2021)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

Influence of physical activity on serum vitamin D levels in people with multiple sclerosis
por: Bauer, Angelika, et al.
Publicado: (2020)

The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review
por: Hegen, Harald, et al.
Publicado: (2019)

Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
por: Hegen, Harald, et al.
Publicado: (2023)

Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum
por: Berek, Klaus, et al.
Publicado: (2023)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Anti-NMDA receptor encephalitis and MOG-associated demyelination – a case report with long-term follow-up and a systematic review
por: Berek, Klaus, et al.
Publicado: (2022)

Longitudinal ventricular cerebrospinal fluid profile in patients with spontaneous subarachnoid hemorrhage
por: Zinganell, Anne, et al.
Publicado: (2022)

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017)

Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery
por: Feige, Julia, et al.
Publicado: (2022)

Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2018)

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study
por: Bsteh, Gabriel, et al.
Publicado: (2016)

Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2023)

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
por: Wurth, Sebastian, et al.
Publicado: (2017)

Smoking is not associated with higher prevalence of JC virus in MS patients
por: Auer, Michael, et al.
Publicado: (2018)

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity
por: Stascheit, Frauke, et al.
Publicado: (2021)

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
por: Auer, Michael, et al.
Publicado: (2019)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Caspr2 antibodies in herpes simplex encephalitis: an extension of the spectrum of virus induced autoimmunity? – A case report
por: Berek, Klaus, et al.
Publicado: (2022)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy
por: Van Looy, Eveline, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1gpd9dqj3s619e9rar9a3sofvl